Daily Ards Research Analysis
Three ARDS-relevant studies stood out: a translational biomarker study showing bronchoalveolar lavage fluid heparin-binding protein (HBP) tracks lung injury better than plasma, a preclinical study identifying esketamine as a mitophagy-activating therapy via ULK1/FUNDC1 signaling, and an observational study linking prolonged mechanical ventilation (>26 days) to poorer survival in severe burns. Together, they advance diagnostic precision, reveal a mitochondria-targeted therapeutic pathway, and und
Summary
Three ARDS-relevant studies stood out: a translational biomarker study showing bronchoalveolar lavage fluid heparin-binding protein (HBP) tracks lung injury better than plasma, a preclinical study identifying esketamine as a mitophagy-activating therapy via ULK1/FUNDC1 signaling, and an observational study linking prolonged mechanical ventilation (>26 days) to poorer survival in severe burns. Together, they advance diagnostic precision, reveal a mitochondria-targeted therapeutic pathway, and underscore the prognostic importance of ventilator duration.
Research Themes
- Biomarkers for ARDS diagnosis and severity assessment
- Mitochondrial quality control (mitophagy) as a therapeutic target in lung injury
- Ventilator management duration as a prognostic marker
Selected Articles
1. Esketamine Regulates Mitophagy through ULK1/FUNDC1 Signaling Pathway to Improve LPS-induced Acute Respiratory Distress Syndrome.
In an LPS-inhalation mouse model of ARDS, esketamine reduced lung injury, vascular permeability, inflammatory cytokines, oxidative stress, and apoptosis. Mechanistically, it activated mitophagy via the ULK1/FUNDC1 pathway, suggesting a mitochondria-targeted therapeutic strategy for ARDS.
Impact: Identifies a mechanistic pathway (ULK1/FUNDC1-mediated mitophagy) through which esketamine confers lung protection, opening a tractable target for ARDS therapeutics and repurposing a clinically available drug.
Clinical Implications: While preclinical, these findings justify early-phase clinical trials of esketamine or ULK1/FUNDC1-targeted strategies in ARDS, and motivate biomarker-led patient selection focusing on mitochondrial stress.
Key Findings
- Esketamine attenuated LPS-induced lung injury, reduced pulmonary vascular permeability, and lowered inflammatory cytokines in BALF and serum.
- It decreased oxidative stress (ROS, MPO) and apoptosis, and restored tight junction protein expression.
- Mechanistically, esketamine activated ULK1/FUNDC1-mediated mitophagy, increasing autophagy/mitophagy markers (e.g., LC3B, FUNDC1).
Methodological Strengths
- Comprehensive multimodal assessment (histology, permeability assays, cytokines, ROS/MPO, apoptosis, autophagy proteins).
- Mechanistic dissection implicating a defined mitophagy pathway (ULK1/FUNDC1).
Limitations
- Preclinical mouse model; translatability to human ARDS is unproven.
- LPS inhalation may not recapitulate the heterogeneity of clinical ARDS; dosing and safety profiles in ARDS populations remain unknown.
Future Directions: Test esketamine dosing, timing, and safety in large-animal models and early-phase ARDS trials; evaluate ULK1/FUNDC1 pathway biomarkers for patient stratification.
BACKGROUND: As a heterogeneous clinical syndrome, acute respiratory distress syndrome (ARDS) is caused by infection-associated inflammation with limited treatment options. Esketamine possesses antiinflammatory properties, and it is effective in treating lung diseases. OBJECTIVE: This study aimed to unveil the efficacy and mechanism of esketamine in ARDS. METHODS: Lipopolysaccharide (LPS) is widely used to induce inflammatory response in lung injury. The mice model of ARDS in this study was established through the inhalation of LPS. Hematoxylin-eosin (H&E) staining was used to evaluate the pathological changes in the lung tissues of ARDS mice, and the histological index of lung damage was employed. Bicinchoninic acid (BCA) assay kits were utilized to assess the total proteins in bronchoalveolar lavage fluid (BALF), and a hemocytometer was used to count the number of total cells. The pulmonary vascular permeability was detected using Evans blue staining. Western blot was carried out to detect the expressions of tight junction proteins, and enzyme-linked immunosorbent assay (ELISA) detected the release of inflammatory cytokines in BALF and serum. Dihydroethidium (DHE) staining was used to detect reactive oxygen species (ROS) production, and the levels of myeloperoxidase (MPO) and oxidative stress markers were measured using corresponding assay kits. Apoptosis was assessed through terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) and Western blot. Immunostaining detected the FUN14 domain-containing 1 (FUNDC1) and light chain 3B (LC3B) in lung tissues, and the expressions of autophagy-related proteins were detected using Western blot. RESULTS: Our data showed that esketamine treatment alleviated LPS-stimulated lung damage, improved pulmonary vascular permeability, and inhibited inflammatory response, oxidative stress, and apoptosis in ARDS mice. Mechanically, esketamine activated mitophagy through UNC-52-like kinase 1 (ULK1)/FUNDC1 signaling pathway. These findings, for the first time, revealed the therapeutic potential of esketamine in treating ARDS. CONCLUSION: Collectively, this study revealed the protective role of esketamine against lung injury, inflammation, oxidative stress, and apoptosis in mice with ARDS and revealed the reaction mechanism related to mitophagy.
2. The value of heparin-binding protein in bronchoalveolar lavage fluid in acute respiratory distress syndrome.
Using both a CLP-induced mouse model and a human comparative study (44 ARDS vs 38 cardiogenic pulmonary edema), BALF and plasma HBP levels were elevated with lung injury and correlated with severity. BALF HBP showed a stronger correlation than plasma HBP, supporting its role as a diagnostic and severity biomarker for ARDS.
Impact: Provides translational evidence that BALF HBP better reflects lung injury than plasma HBP and differentiates ARDS from cardiogenic pulmonary edema, which can refine diagnosis and management.
Clinical Implications: BALF HBP could be incorporated into diagnostic algorithms to distinguish ARDS from cardiogenic edema and to stage severity, particularly when BAL is clinically indicated.
Key Findings
- In CLP-induced mice, lung wet-to-dry ratio, BALF protein, BALF HBP, and plasma HBP were significantly higher than controls and correlated with injury severity.
- In humans (44 ARDS vs 38 CPE), BALF HBP, BALF protein, and plasma HBP differed significantly between groups and correlated with lung injury severity.
- BALF HBP had a stronger correlation with lung injury than plasma HBP, suggesting superior utility as a biomarker.
Methodological Strengths
- Translational design integrating animal modeling with human comparative analysis.
- Direct comparison with cardiogenic pulmonary edema, a key clinical differential for ARDS.
Limitations
- Modest human sample size and cross-sectional design limit causal inference.
- BALF sampling is invasive and may not be feasible in all ARDS patients; timing relative to disease course may influence levels.
Future Directions: Validate BALF HBP thresholds prospectively, assess temporal kinetics, and develop less-invasive surrogates (e.g., exhaled breath condensate) reflecting alveolar HBP.
BACKGROUND: Heparin-binding protein (HBP) is recognized as a significant factor in the development of Acute Respiratory Distress Syndrome (ARDS). Although plasma levels of HBP have been identified as a predictive biomarker for ARDS, the role and value of HBP in bronchoalveolar lavage fluid (BALF) remain unexplored. METHODS: Our study utilized a cecum ligation and puncture (CLP) method to induce an ARDS model in mice, examining the correlations between plasma and BALF HBP levels, lung injury severity, lung wet-to-dry (WD) ratio, and BALF total protein levels. Additionally, we conducted a comparative analysis of BALF and plasma HBP levels in 44 ARDS patients and 38 patients with cardiogenic pulmonary edema (CPE), investigating their correlations. RESULTS: In the animal study, CLP-induced mice demonstrated significantly higher lung WD ratios, BALF protein, BALF HBP, and plasma HBP levels compared to the control group. Notably, both BALF and plasma HBP levels were significantly correlated with lung injury severity. In human subjects, significant differences in BALF HBP, BALF protein, and plasma HBP levels were observed between ARDS and CPE patients, along with notable correlations between these markers and the severity of lung injury. Particularly, BALF HBP levels exhibited a stronger correlation with lung injury compared to plasma HBP levels. CONCLUSION: The study indicates that both BALF and plasma HBP levels are significantly elevated in the context of lung injury in both animal models and human ARDS patients. More importantly, BALF HBP levels show a stronger correlation with the severity of lung injury, suggesting that BALF HBP could serve as a valuable biomarker for diagnosing and guiding the treatment of ARDS.
3. Proper early weaning from ventilator assistance influences the overall survival of patients with severe burns: A case-control study.
In a case-control analysis of 185 severe burn patients with external validation (n=144), ventilator assistance beyond 26 days was linked to significantly shorter overall survival. Ventilator days also correlated with burn area and complications including inhalation injury, sepsis, DIC, AHF, AKI, ALF, and ARDS.
Impact: Highlights ventilator duration as a modifiable prognostic factor supported by external validation, informing targets for early weaning strategies in critical care, including patients at risk for ARDS.
Clinical Implications: Implement protocols that prioritize early, safe weaning once spontaneous breathing recovers, and use ventilator days (>26) as a prognostic warning sign warranting aggressive complication prevention.
Key Findings
- Ventilator assistance >26 days was significantly associated with shorter overall survival (P<0.001).
- Ventilator days correlated with burn area and combined complications including inhalation injury, sepsis, DIC, AHF, AKI, ALF, and ARDS.
- Prognostic value of ventilator days was externally validated in an independent cohort (n=144).
Methodological Strengths
- Multivariable Cox regression with comprehensive model diagnostics (residuals, calibration, decision curves, ROC).
- External validation in an independent cohort.
Limitations
- Observational case-control design cannot establish causality; prolonged ventilation may reflect severity/reserve rather than cause mortality.
- Single-condition context (severe burns) may limit generalizability to other ARDS populations.
Future Directions: Prospective interventional trials testing early weaning bundles and sedation/analgesia strategies to shorten ventilator days, with ARDS-specific subanalyses.
BACKGROUND: Ventilator assistance is crucial in the treatment of severely burned patients. However, there is no consensus on the optimal duration of ventilator assistance, and whether it has an impact on the short - and long-term prognosis of severely burned patients is still unclear. METHODS: We incorporated 185 severely burned patients in our study. Kaplan-Meier analysis and Chi-square tests were applied to reveal the associations of days of ventilator assistance with patients' overall survival (OS) and other clinical variables. Multivariable Cox regression was applied, and the model was diagnosed by residual analysis, calibration curve analysis, decision curve analysis, and receiver operating characteristic curve analysis. 144 burned patients in Changhai Cohort were used for external validation. RESULTS: Ventilator assistance >26 days was significantly associated with a shorter OS in severely burned patients (P-value <0.001). Besides, "days of ventilator assistance" was significantly correlated with the burn area (P-value <0.001), and the combination of inhalation injury (P-value <0.01), sepsis, DIC, AHF, AKI, ALF, and ARDS (P-value <0.001). The prognostic value of "days of ventilator assistance" was further validated in Changhai Cohort. CONCLUSION: Prolonged ventilator assistance was associated with decreased OS in severely burned patients. Under the premise of the recovery of spontaneous respiratory function, early weaning from ventilator assistance might improve the prognosis of patients with severe burns. The findings on the optimal duration of ventilator assistance and its impact on survival in severely burned patients would interest healthcare professionals in respiratory and critical care medicine.